AGTR1
Type-1 angiotensin II receptor
As of the edition of 20 October 2026, AGTR1 (type-1 angiotensin II receptor, UniProt P30556) has 20 drugs tested at it and 33 companies on the list, 0 on route A and 17 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P30556
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 15
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Urinary and reproductive; Pregnancy and women's health; Hormones; Infections; Nervous system; Lungs and airways
- Registered trials of its drugs
- 1,214
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 14 |
| Active | 2 |
| Went quiet | 2 |
| Stopped | 2 |
| Total | 20 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Valsartan | Marketed | Phase 4 | none listed |
| Losartan | Marketed | Phase 4 | none listed |
| Telmisartan | Marketed | Phase 4 | none listed |
| Irbesartan | Marketed | Phase 4 | none listed |
| Candesartan | Marketed | Phase 4 | none listed |
| Olmesartan medoxomil | Marketed | Phase 4 | none listed |
| Candesartan cilexetil | Marketed | Phase 4 | none listed |
| Fimasartan | Stopped | Phase 4 | none listed |
| Angiotensin ii | Marketed | Phase 4 | none listed |
| Azilsartan medoxomil | Marketed | Phase 4 | none listed |
| Olmesartan | Marketed | Phase 4 | none listed |
| Azilsartan | Marketed | Phase 4 | none listed |
12 of 20 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 17 |
| Engaged | 10 |
| Undetermined | 6 |
| Total on the list | 33 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Boehringer Ingelheim | Route B |
| Sanofi | Route B |
The other 30 companies at AGTR1
In the product33 companies in all; 30 are not named here, and no score is.
See the 33 companies at AGTR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.